Related Articles
Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer
EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab